Ran Nussbaum - 06 Jun 2022 Form 4/A - Amendment Insider Report for UroGen Pharma Ltd. (URGN)

Role: Director
Signature: /s/ Jason D. Smith, Attorney-in-Fact
Issuer symbol: URGN
Transactions as of: 06 Jun 2022
Net transactions value: +$5,150
Form type: 4/A - Amendment
Filing time: 28 Feb 2023, 11:29:13 UTC
Date Of Original Report: 25 Aug 2022
Previous filing: 03 Jun 2022
Next filing: 10 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	URGN	Ordinary Shares	Options Exercise	$5,150	+1,030	+0.07%	$5.00^*	1,434,958	06 Jun 2022	Managing member of entities affiliated with Pontifax Management III G.P. (2011) Ltd.	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	URGN	Stock Option (right to buy)	Options Exercise	$0	-1,030	-100%	$0.000000^*	0	06 Jun 2022	Ordinary Shares	1,030	$5.00	By Pontifax Cayman III Limited Partnership	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On August 25, 2022, the reporting person filed a Form 4 that inadvertently reported 1,433,928 shares of securities beneficially owned following reported transaction instead of 1,434,958 shares.
F2	On August 25, 2022, the reporting person filed a Form 4 that inadvertently list the expiration date as August 31, 2022.